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Rationale: FVC has emerged as a standard primary endpoint in clinical trials evaluating novel 
therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently been 
proposed that all-cause mortality or a composite comprised of all-cause mortality and all-cause 
nonelective hospitalization be adopted as the standard primary endpoint for IPF clinical trials. 
Objectives: To conduct a comprehensive evaluation of mortality in three phase 3 clinical trials and 
evaluate the feasibility of mortality trials in patients with IPF. 
Methods: The study population included 622 patients randomized to placebo in the CAPACITY 
studies evaluating pirfenidone (n = 347) or the INSPIRE study evaluating interferon-γ1b (n = 275). 
The Kaplan-Meier estimate of 2-year survival was fit to the exponential distribution and used to 
calculate sample size requirements for a mortality study with 90% power to detect a 25% 
reduction in all-cause mortality with a two-sided α of 0.05. Modeling analyses were used to assess 
the effects of selected variables on sample size and study design. 
Measurements and Main Results: A total of 73 deaths occurred during the period of observation 
(mean duration of follow-up, 80.1 wk). The all-cause mortality rate was 6.6% at 1 year and 13.7% 
at 2 years. Based on the observed 2-year mortality rate, a total of 508 events would be required to 
detect a significant treatment benefit in a two-arm trial with 90% power to detect a 25% reduction 
in all-cause mortality. The estimated sample size for a trial enrolled over 3 years with a maximum 
follow-up period of 5 years is 2,582 patients. 
Conclusions: The all-cause mortality rate is relatively low in patients with IPF with mild to 
moderate impairment in lung function. Accordingly, the necessary size, duration, and cost of all-
cause mortality trials in this population are substantial and likely prohibitive. 
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Idiopathic pulmonary fibrosis (IPF) is a chronic, relentlessly progressive, fatal lung disease for 
which there is no known cause or cure. The clinical course is characterized by progressively 
worsening dyspnea and irreversible declines in lung volume and exercise capacity that limit and 
eventually preclude routine physical activity (1). 
During the last decade there has been a substantial increase in the number of randomized 
controlled trials evaluating therapies for patients with IPF. FVC has emerged as a standard primary 
endpoint in phase 3 registration trials, supporting IPF drug approvals in multiple countries in 
Europe, North America, Asia, and Latin America. Moreover, FVC is the primary endpoint in each of 
the four ongoing phase 3 clinical trials in patients with IPF (2–5). However, it has recently been 
proposed that all-cause mortality or a composite endpoint comprised of all-cause mortality and 
all-cause nonelective hospitalization should be adopted as the standard primary endpoint for 
therapeutic clinical trials in patients with IPF (6). 
To explore the feasibility of mortality trials in the setting of a highly efficacious therapy, we 
conducted a comprehensive evaluation of mortality outcomes in three phase 3 global clinical trials 
in patients with IPF with mild to moderate impairment in baseline measures of physiologic 
function. These data were then used as the basis for power calculations and sample size estimates 
for a theoretical, randomized, double-blind, placebo-controlled trial designed to detect a 
statistically significant treatment effect on all-cause mortality in patients with IPF. This study has 
been presented in part at the 2013 International Conference of the American Thoracic Society (7). 
 
 
METHOD 
Study Population 
All patients randomized to the placebo group in the CAPACITY studies (8) evaluating treatment 
with pirfenidone (n = 347) or the INSPIRE study (9) evaluating interferon-γ1b (n = 275) were 
included in the analysis. 
Criteria for enrollment in the INSPIRE trial (GIPF-007) included a confident diagnosis of IPF 
according to protocol-defined criteria, evidence of clinical worsening within the preceding year, 
baseline percent predicted FVC greater than or equal to 55%, and baseline percent predicted 
diffusing capacity of carbon monoxide (DlCO) greater than or equal to 35% (9). Eligibility criteria for 
the CAPACITY studies (Study 004 and Study 006) included a confident diagnosis of IPF according to 
protocol-defined criteria within the preceding year, baseline percent predicted FVC greater than 
or equal to 50%, baseline percent predicted DlCO greater than or equal to 35%, and either baseline 
percent predicted FVC or percent predicted DlCO less than or equal to 90% (8). Criteria mandating 
exclusion from all three trials included a history of clinically significant environmental exposure 
known to cause pulmonary fibrosis; unstable or deteriorating cardiac or pulmonary disease (other 
than IPF) within the previous 6 months; a diagnosis of connective tissue disease; clinical evidence 
of active infection; or any alternative explanation for interstitial lung disease. Eligible patients 
were also not permitted to be on a waiting list for lung transplantation at the time of 
randomization. 
Statistical Analyses 
A series of comprehensive analyses was undertaken to explore mortality outcomes in the pooled 
population of patients from the placebo groups in the INSPIRE and CAPACITY studies. Outcomes 
that were assessed included overall survival, cause of death, relatedness of death to the 
underlying respiratory disease, and the relationship between mortality and baseline lung function. 
Demographic and baseline characteristics are summarized using descriptive statistics for 
continuous variables, and number and percentage counts of patients for categorical variables. 
Overall survival data are summarized as Kaplan-Meier estimates of the probability of survival in 
the pooled population. Cause of death was assigned by the principal investigator based on clinical 
judgment and coded according to system organ class as defined in the Medical Dictionary for 
Regulatory Activities. Additionally, deaths were characterized as IPF-related or not IPF-related by 
clinical investigators who were masked to treatment assignment. 
To explore the feasibility of a clinical trial designed to assess the effect of an intervention on 
mortality in patients with IPF, the Kaplan-Meier estimate of 2-year survival was fit to the 
exponential distribution and used to calculate sample size requirements for a mortality study with 
90% power to detect a 25% reduction in all-cause mortality (hazard ratio [HR], 0.75) with a two-
sided α of 0.05. A modeling analysis was conducted to assess the effect of deaths that are either 
indirectly related or unrelated to IPF on the magnitude of effect on directly related deaths 
required to achieve a HR of 0.75 for all-cause mortality under a range of assumptions regarding 
the effect of treatment on indirectly related deaths. The estimated proportion of indirectly related 
deaths in the model was based on clinical judgment and informed by the proportion of deaths 
assessed by clinical investigators as either IPF-related or unrelated to IPF in previous phase 3 
clinical trials (8, 9). Directly related death was defined as death caused by progression of disease 
or acute exacerbation; indirectly related death was defined as death caused by a respiratory or 
nonrespiratory cause or event in which IPF contributed indirectly but in a clinically significant way 
(e.g., pneumonia). Study sample size, randomization (1:1), enrollment, and duration of follow-up 
were held constant in the model. 
 
RESULTS 
Patient Characteristics 
A total of 622 patients were included in the analysis. The median (range) age at baseline was 67 
(40−80) years; median (range) values for percent predicted FVC and percent predicted DlCO were 
71.7 (48.0−135.5) and 45.6 (17.1−90.1), respectively (Table 1). High-resolution computed 
tomography findings were interpreted by radiologists at the study sites as consistent with the 
protocol-defined criteria for a diagnosis of “definite IPF” in 89.5% of patients. High-resolution 
computed tomography findings were interpreted as consistent with the protocol-defined criteria 
for a diagnosis of “probable IPF” in 10.5% of patients; in accordance with the protocol, the 
diagnosis was subsequently confirmed by surgical lung biopsy in all such patients. 
tic Value* (n = 622) 
Age, yr 67.0 (40–80) 
Male, % 70.6 
White, % 96.3 
FVC, % predicted 71.7 (48.0–135.5) 
Dlco, % predicted 45.6 (17.1–90.1) 
6MWT distance, m 400.0 (42.0–750.0) 
Time since IPF diagnosis, yr 0.7 (0–5.0) 
HRCT “definite IPF,” % 89.5 
Supplemental O2 use, % 18.5 
Definition of abbreviations: 6MWT = 6-minute-walk test; DlCO = carbon monoxide diffusing 
capacity; HRCT = high-resolution computed tomography; IPF = idiopathic pulmonary fibrosis. 
*Values are expressed as the median (range) unless otherwise indicated. 
 
 
Demographics and Baseline Characteristics. 
Mortality Outcomes 
Vital status was ascertained in 612 of 622 (98.4%) patients. A total of 73 deaths occurred during 
the observation period (mean duration of follow-up, 80.1 wk); of these, 61 (83%) were judged by 
clinical investigators to be IPF-related. The all-cause mortality rate was 6.6% at 1 year and 13.7% at 
2 years (Figure 1). 
Figure 1 
 
 
Figure 1. Kaplan-Meier estimate of overall survival in the pooled placebo populations from the 
INSPIRE and CAPACITY studies. 
 
Kaplan-Meier estimate of overall survival in the pooled placebo populations from the INSPIRE and 
CAPACITY studies. 
The absolute risk of mortality by baseline physiologic impairment is summarized in Figure 2. 
Consistent with prior research (10–12), graded relationships were observed between baseline 
percent predicted FVC and the crude risk of both all-cause and IPF-related mortality. Death from 
any cause occurred in 21% of patients with a baseline percent predicted FVC value less than 65%, 
compared with 14.7% in patients with baseline percent predicted FVC values between 65 and 80%, 
and 6.1% in patients with baseline FVC values greater than or equal to 80%. 
Figure 2 
 
 
 
 
 
 
 Figure 2. Risk of mortality by baseline physiologic impairment. *Assessed by clinical investigators 
who remained blinded to treatment assignment. IPF = idiopathic pulmonary fibrosis. 
 
Risk of mortality by baseline physiologic impairment. [More] 
Cause of death is summarized in Table 2. The primary cause of death was reported as respiratory, 
thoracic, and mediastinal disorders in 47 (7.6% of the total study population) patients. Cardiac 
disorders (7 [1.1%] patients), general disorders (7 [1.1%] patients), and infections and infestations 
(6 [1.0%] patients) were the only other causes of death with an incidence greater than or equal to 
1%. 
Table 2: Cause of Death 
System Organ Class* N (%) 
Respiratory, thoracic, and mediastinal disorders 47 (7.6) 
Cardiac disorders 7 (1.1) 
General disorders/administration site conditions 7 (1.1)† 
Infections and infestations 6 (1.0) 
Neoplasms, benign, malignant, and unspecified 5 (0.7) 
Gastrointestinal disorders 1 (0.2) 
*As defined in the Medical Dictionary for Regulatory Activities. 
†Includes two cases of “disease progression,” one case of “condition aggravated,” and one case of 
“sudden death.” 
 
 
Cause of Death. 
Sample Size Calculation: IPF Mortality Trial 
The observed 2-year mortality rate of 13.7% was used to calculate the estimated sample size for a 
two-arm study (1:1 randomization) with 90% power to detect a 25% reduction in all-cause 
mortality (HR, 0.75). Assuming vital status is ascertained in greater than or equal to 95% of study 
participants, a total of 508 all-cause mortality events would be required to reject the null 
hypothesis. Based on an enrollment period of 3 years and a maximum follow-up period of 5 years, 
such a trial would require a sample size of 2,582 patients (Figure 3A). A substantially larger sample 
size would be required to detect a more modest treatment effect; based on the same assumptions 
regarding study power (90%) and 2-year mortality rates (13.7%), a sample size of more than 
17,000 patients would be required to detect a 10% reduction (HR, 0.90) in all-cause mortality 
(Figure 3B). 
Figure 3 
 
 
Figure 3. Power calculations and sample size estimates for mortality trials in idiopathic pulmonary 
fibrosis. (A) Sample size requirements for a trial with a 3-year enrollment period, 2 years of follow-
up, and a hazard ratio of 0.75 (log-rank test for survival in two groups followed for fixed time with 
a fixed hazard ratio). (B) Sample size requirements for a two-arm trial with a 3-year enrollment 
period, 2 years of follow-up, and 90% power to detect a treatment effect with a two-sided α of 
0.05 (log-rank test for survival in two groups followed for fixed time with fixed power and a 
constant hazard ratio over time). 
 
 
 
 
Power calculations and sample size estimates for mortality trials in idiopathic pulmonary fibrosis.  
To examine the effect of deaths that are not directly related to the underlying disease biology on 
the required magnitude of treatment effect on deaths that are presumably amenable to 
antifibrotic therapy, HRs for directly related deaths were calculated for a range of scenarios (Table 
3). Calculations were based on an overall 25% reduction in all-cause mortality among patients 
randomized to active treatment. If treatment reduced indirectly related deaths by 30% (HR, 0.70), 
a similar reduction in directly related deaths (HR, 0.70) would be required to achieve a 25% 
reduction in all-cause mortality. Under a scenario in which treatment has no effect on indirectly 
related deaths, a nearly 50% reduction in directly related deaths would be required to achieve a 
25% reduction in all-cause mortality (HR, 0.75). 
 
DISCUSSION  
Recently, an expert working group convened to deliberate on the selection of clinically meaningful 
endpoints in phase 3 clinical trials in IPF concluded that all-cause mortality and all-cause 
nonelective hospitalization represent the most scientifically robust and clinically meaningful 
primary endpoints for therapeutic trials in patients with IPF (6). Based on this conclusion, the 
group proposed that, in the absence of a valid and reliable surrogate for mortality, a composite 
endpoint comprised of all-cause mortality and all-cause nonelective hospitalization should be 
adopted as the standard primary endpoint for clinical trials in patients with IPF. Although all-cause 
mortality inarguably satisfies the criterion of a scientifically rigorous and clinically meaningful 
endpoint in patients with a fatal disease, the practicality and cost of executing a properly powered 
mortality trial in patients with IPF have not been rigorously examined. In the present analysis, we 
conducted a comprehensive evaluation of mortality in a large and well-defined cohort of patients 
with IPF with mild to moderate impairment in lung function who were randomized to treatment 
with placebo in one of three large phase 3 clinical trials and followed prospectively for a mean 
duration of 80 weeks. 
Our findings show that the all-cause mortality rate is relatively low in patients with IPF with mild to 
moderate impairment in baseline measures of physiologic function and, importantly, 
approximately one in five die from causes that are unrelated to IPF. Accordingly, the necessary 
size, duration, and cost of all-cause mortality trials in this population are substantial and likely 
prohibitive. Based on the results of our analysis, we estimate that a properly powered trial (1-β = 
0.9) designed to detect a 25% reduction in all-cause mortality among patients with IPF with mild to 
moderate physiologic impairment would require a sample size of nearly 2,600 patients and cost 
approximately $250 million (13, 14). Moreover, the estimated time from study initiation to 
regulatory approval of the study drug, assuming the study results provide statistically persuasive 
evidence of a meaningful therapeutic benefit, would be nearly 7 years. 
It is tempting to speculate based on the observed graded relationship between baseline lung 
function and mortality that the challenges associated with the design and execution of mortality 
trials in patients with IPF with mild to moderate physiologic impairment might be addressed in 
part by enrolling patients with moderate to severe functional impairment. Indeed, mortality 
studies in patients with advanced disease offer the theoretical advantages of higher event rates, 
smaller sample sizes, and shorter trial duration. However, the disease is not well characterized in 
this population and insufficient data exist to reliably inform estimates of sample size and study 
duration. Moreover, such comorbidities as pulmonary hypertension and end-stage irreversible 
fibrosis are markedly more prevalent in this population, further reducing the proportion of deaths 
that are likely to be amenable to antifibrotic therapy. 
An additional challenge in the design of mortality trials in patients with IPF arises from the need to 
rely on mortality outcomes in underpowered studies to guide assumptions regarding the expected 
magnitude of treatment effect. Importantly, assessments of mortality in underpowered studies 
are limited by the instability of the estimates of treatment effect and therefore lack sufficient 
precision to inform the design of phase 3 mortality trials. For example, assuming a 6% annual 
mortality rate, a two-arm trial (1:1 randomization) enrolling 500 patients would have 20% chance 
of observing a HR greater than 1.0 if truth = HR 0.75; if truth = HR 0.90 (a magnitude of effect that 
is comparable with the observed effect of several approved therapies for cardiovascular disease 
and non–small lung cancer) the chance of observing a HR greater than 1.00 would increase to 
nearly 40% (Figure 4). 
Figure 4 
 
 
Figure 4. Probability of type II error in trials underpowered to assess mortality, based on a two-
arm trial with 1:1 randomization, 250 patients per group, and a 6% annual event rate in the 
placebo group. HR = hazard ratio. 
 
Probability of type II error in trials underpowered to assess mortality, based on a two-arm trial 
with 1:1 randomization, 250 patients per group, and a 6% annual event rate in the placebo group. 
[More] 
Furthermore, the sample size requirement of 2,600 patients in our analysis is based on the 
assumption of a 25% reduction in all-cause mortality among patients randomized to treatment 
with the study drug, a magnitude of effect that is substantially larger than the observed effect of 
drugs that are commonly used to reduce the risk of mortality in other diseases. In a metaanalysis 
of 76 trials evaluating the effect of statins in 170,255 patients with a risk factor for a 
cardiovascular event, Mills and coworkers (15) reported a 10% reduction in all-cause mortality 
(relative risk, 0.90; 95% confidence interval, 0.86–0.94). This finding was consistent with four other 
metaanalyses evaluating the effect of statins on cardiovascular events; relative risks for all-cause 
mortality in these studies ranged from 0.84 to 0.89 (16–19). Additionally, in an analysis of 
randomized, double-blind, placebo-controlled trials evaluating molecular-targeted therapies for 
stage IIIB–IV non–small cell lung cancer, Hotta and coworkers (20) identified 11 trials evaluating 
three currently approved agents for which overall survival was a primary or secondary endpoint. 
HRs for all-cause mortality ranged from 0.70 to 1.60, with only 1 of 11 identified trials reporting a 
HR less than 0.80 and 7 of the 11 trials reporting a HR greater than or equal to 0.90. Detecting a 
comparable magnitude of treatment effect on all-cause mortality (HR, 0.90) in a trial enrolling 
patients with IPF with mild to moderate functional impairment would require more than 17,000 
patients and cost hundreds of millions of dollars. In the context of an orphan disease, such a trial is 
clearly impracticable. 
Based on these observations, we believe that the adoption of all-cause mortality as a primary 
endpoint for IPF clinical trials, although scientifically rigorous and of indisputable clinical relevance, 
is both impractical and cost-prohibitive. For these reasons, we believe that objective measures of 
lung function and functional status represent the most appropriate measures of clinical efficacy 
for therapeutic clinical trials in IPF. Our conclusion is supported by several lines of evidence. First, 
both FVC and 6-minute walk test distance (6MWD) have been shown to be reliable, valid, and 
responsive measures of disease status (10, 19), and longitudinal changes in FVC and 6MWD are 
strong independent predictors of mortality in patients with IPF (11, 12, 21–25). Second, recent 
estimates for the minimal clinically important difference for FVC (10) and 6MWD (26–29) have 
established clear thresholds for evaluating the clinical relevance of an observed magnitude of 
treatment effect in IPF clinical trials. Third, analysis of outcomes in two large, randomized, double-
blind, placebo-controlled trials in patients with IPF suggests that a novel composite for disease 
progression defined on the basis of categorical decrements in FVC and 6MWD increases event 
rates and has the potential to improve clinical trial efficiency (30). Finally, FVC has been 
established as a standard primary efficacy endpoint in phase 3 clinical trials in IPF (2–5), 
supporting the regulatory approval of an IPF therapy in several countries in Europe, Asia, North 
America, and Latin America (8). 
The findings of our study should be interpreted in the context of several important limitations. 
First, the magnitude of treatment effect used in the sample size calculation and modeling exercise 
was arbitrarily selected, because there were insufficient data to reliably inform estimates of the 
magnitude of effect that can be reasonably anticipated in therapeutic trials in patients with IPF. 
Accordingly, the extent to which a 25% reduction in all-cause mortality represents an achievable 
outcome in IPF clinical trials is uncertain. However, as noted previously, relevant benchmarks in 
lung cancer and cardiovascular disease suggest that our assumption regarding the magnitude of 
treatment effect was comparatively large and therefore provided a conservatively small estimate 
of sample size (15–20). 
Second, our assumptions regarding the estimated proportion of deaths in patients with IPF that 
are indirectly related to IPF were based on clinical judgment and the “relatedness” of death to the 
underlying fibrotic disease was not formally adjudicated. We note, however, that the chief aim of 
this particular analysis was limited to illustrating the relative impact of deaths that are not related 
to the underlying disease biology on the observed magnitude of treatment effect in a trial that is 
powered to assess the effect of an antifibrotic agent on all-cause mortality. Although the 
necessary magnitude of treatment effect on deaths that are directly related to IPF varies according 
to both the proportion of deaths that are not directly related to IPF and the degree to which such 
deaths are amenable to intervention with the study drug, the model illustrates an important 
concept that should be borne in mind when assessing the feasibility of all-cause mortality as a 
primary endpoint in IPF clinical trials. 
Third, our analyses were limited to mortality outcomes and the feasibility of all-cause mortality as 
a standard primary endpoint in therapeutic clinical trials in patients with IPF. We did not evaluate 
the feasibility of the composite primary endpoint comprised of all-cause mortality and all-cause 
nonelective hospitalization that was recently proposed by Raghu and coworkers (6). Our decision 
was based on the limitations of all-cause nonelective hospitalization as an endpoint, including 
broad regional variability in hospitalization patterns and the possibility that the reason for 
hospitalization may be unrelated to the underlying disease biology. Additionally, unlike FVC and 
6MWD, hospitalization has not been validated as an outcome in a clinical trial in patients with IPF. 
Although we have shown that a clinical risk prediction model comprised of age, respiratory 
hospitalization, percent FVC, and 24-week change in percent FVC reliably predicts 1-year mortality 
in patients with IPF (12), the prognostic significance of all-cause nonelective hospitalizations has 
not been evaluated. Moreover, as noted by Raghu and coworkers (6), a correlation between an 
endpoint and mortality is insufficient evidence to demonstrate that the endpoint is a reliable 
surrogate for mortality. The observed correlation between respiratory hospitalization and 
mortality, although informative in the formulation of an individual patient’s prognosis, is 
insufficient to establish respiratory hospitalizations as a reliable surrogate for mortality and, in the 
absence of evidence to demonstrate the validity of either respiratory hospitalizations or all-cause 
nonelective hospitalizations as a clinical endpoint, the feasibility of primary endpoints based on 
hospitalizations in IPF clinical trials cannot be adequately evaluated. 
Fourth, the power calculations and sample size estimates for a mortality trial in patients with mild 
to moderate physiologic impairment were based in part on the Kaplan-Meier 2-year survival 
estimates, with a planned trial enrollment period of 3 years and a follow-up period of 2 years. 
Although the stability of the estimates over 2 years suggests that mortality rates are unlikely to 
increase substantially among patients who remain in the trial beyond the first 2 years of follow-up, 
such a possibility cannot be excluded (31). Therefore, increasing the study duration could decrease 
the sample size requirements. We believe, however, that the challenges of executing trials of 
longer duration (including increased cost, decreased patient retention, and an increase in the 
prevalence of comorbidities over time) limit the feasibility of this approach. 
Finally, our analysis was limited to patients with mild to moderate impairment in baseline 
measures of physiologic function; therefore, the degree to which conclusions regarding the 
feasibility of mortality trials can be extended to patients with severe physiologic impairment is 
uncertain. As noted previously, however, the design and execution of properly powered mortality 
trials in this population is confounded by the increased proportion of patients with end-stage 
fibrosis and comorbid conditions, and the paucity of data to guide estimates of sample size and 
study duration. 
In summary, our results demonstrate that all-cause mortality rates are relatively low in patients 
with IPF and mild to moderate physiologic impairment. However, patients with IPF suffer real and 
meaningful consequences from their disease and therapies aimed at attenuating disease 
progression are urgently needed. Patients’ interests are therefore best served by efficient clinical 
trials of limited size and duration that compress drug development timelines and attract further 
investment in the field, thereby optimizing access to novel therapeutic interventions that slow 
disease progression and preserve patients’ quality of life. 
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